Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Instagram Outage Disrupts Thousands of U.S. Users 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
REDWOOD CITY, Calif., Feb. 01, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today is pleased to announce the appointment of Jim Daly as Executive Chairman, Commercial Advisory Committee. Mr. Daly is a biopharmaceutical executive with over 30 years of experience leading U.S. and global businesses.
“We are extremely pleased to welcome Jim to the Coherus team,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “He is an accomplished commercial executive with a stellar track record who brings a wealth of experience, insight and leadership to address key issues as we build our commercial capabilities. Over the course of his career, Jim has created market-leading global franchises across multiple therapeutic categories, most recently in oncology and inflammation. With CHS-1701 (biosimilar pegfilgrastim), our lead oncology asset, successfully meeting both primary endpoints in its antigenicity registration study and the Biologics License Application (BLA) filing approaching, we are excited to benefit from Jim’s knowledge and expertise.”
Mr. Daly will lead the Coherus Commercial Advisory Committee and advise the organization on key strategic commercial issues related to sales, marketing, pricing, contracting, channel strategy development, new product planning and business development.
“I am excited to join Coherus,” said Mr. Daly. “The team is comprised of individuals who helped pioneer the biotech industry. They have joined together and are driven by a common mission to bring the benefits of breakthrough biologics to more patients in more markets. CHS-1701 is a key asset in the Coherus oncology franchise, and we believe it will pave the way for additional follow on biosimilars in this therapeutic area, unlocking the oncology market potential. It’s important for patients, providers, payers as well as for the healthcare system as a whole that high quality biosimilar therapeutics achieve their full potential to expand access and control costs.”
Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. Prior to Incyte, Mr. Daly worked for Amgen for 10 years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. His teams at Amgen were responsible for the successful commercialization of many biologics, including Neulasta®, Enbrel®, Aranesp®, Vectibix®, Nplate®, Xgeva® and Prolia®. Previously, Mr. Daly spent over 16 years with GlaxoSmithKline, where he held roles of increasing responsibility, including Senior Vice President, General Manager of the Respiratory and Anti-Infective Division, and led the U.S. launch of Advair®. He currently serves on the Boards of Directors of Chimerix, Inc. and Acadia Pharmaceuticals. Jim earned both his M.B.A. and B.S. in Pharmacy from the State of University of New York at Buffalo.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit www.coherus.com.
Neulasta®, Enbrel®, Aranesp®, Vectibix®, Nplate®, Xgeva® and Prolia® are registered trademarks of Amgen Inc. Advair® is a registered trademark of Glaxo Group Limited.
INVESTOR AND MEDIA CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239
